Repligen to Report Second Quarter 2024 Financial Results
July 16, 2024 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2024 financial results on Tuesday, July 30, 2024....
Repligen Announces CEO Transition Plan
June 13, 2024 07:00 ET
|
Repligen Corporation
WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that its Board of...
Repligen Corporation to Present at Upcoming June Investor Conferences
May 22, 2024 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be...
Repligen Corporation to Present at Upcoming May Investor Conferences
May 07, 2024 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be...
Repligen Reports First Quarter 2024 Financial Results
May 01, 2024 07:30 ET
|
Repligen Corporation
Reports first quarter revenue of $151 million Increased new modalities revenue by 16% year-over-yearIncreased Filtration (non-COVID) revenue by 12% year-over-yearAchieved a nine-month book-to-bill...
Repligen to Report First Quarter 2024 Financial Results
April 17, 2024 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2024 financial results on Wednesday, May 1, 2024....
Repligen Appoints Maggie A. Pax to Board of Directors
March 19, 2024 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences industry executive Maggie A. Pax....
Repligen Reports Fourth Quarter and Full Year 2023 Financial Results
February 21, 2024 07:30 ET
|
Repligen Corporation
Reports fourth quarter revenue of $156 million and full year revenue of $639 million Continued strength in orders with fourth quarter book-to-bill ratio of 1.03 WALTHAM, Mass., Feb. 21, 2024 ...
Repligen to Report Fourth Quarter and Full Year 2023 Financial Results
February 07, 2024 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter 2023 financial results on Wednesday, February 21,...
Repligen Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
December 19, 2023 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at...